<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725424</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-071</org_study_id>
    <nct_id>NCT02725424</nct_id>
  </id_info>
  <brief_title>Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer</brief_title>
  <acronym>MATCH</acronym>
  <official_title>A Randomized, Multicenter, Controlled Phase II Study to Compare Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gastric/Gastroesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized,phase II,open-label study, The purpose of this study is to determine the
      optimal treatment for patients with locally advanced Gastric/Gastroesophageal Cancer
      according to their Her-2 expression status.

      The primary endpoint of this study: pathology response rate the second endpoints of this
      study:pathology complete response rate R0 resection rate Progression-free survival ( PFS)
      Disease -free survival (DFS) Overall survival(OS) Objective response rate(ORR) Adverse
      event(AE)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (human epidermal growth factor receptor-2,HER2) positive patients: After 4 weeks of
      SOX±Trastuzumab Neoadjuvant therapy, those who show CR(complete response) or PR(partial
      response) by Resist evaluation will continue with D2 surgery , then 4cycles of
      SOX±Trastuzumab Adjuvant chemotherapy, and 4cycles of Trastuzumab as maintenance therapy;
      those who do not response to former therapy or progress, will be treated with
      surgery,concurrent chemoradiotherapy,or 2th line chemotherapy.

      (human epidermal growth factor receptor-2,HER2) negative patients： After 4 weeks of DOS or
      SOX regimen as neoadjuvant therapy, those who show CR(complete response) or PR(partial
      response) by Resist evaluation will continue with D2 surgery , then 4cycles of SOX adjuvant
      chemotherapy, those who do not response to former therapy or progress, will be treated with
      surgery,concurrent chemoradiotherapy,or 2th line chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>40 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Her2 Positive with SOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Her-2 Positive patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin 130 mg/m2, iv, d1 S-1 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), po,Bid， d1-14 Every 3weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Her-2 positive patients treated with Oxaliplatin plus S-1 and Trastuzumab Oxaliplatin : As Above S-1: As Above Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 Negative with SOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Her2 Negative patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin As Above S-1 As Above Every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Her-2 Negative patients treated with Docetaxel plus Oxaliplatin and S-1（DOS） Docetaxel 60 mg/m2, iv, d1 Oxaliplatin 100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Her-2 Positive patients with SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), po,Bid， d1-14 Every 3weeks.</description>
    <arm_group_label>Her2 Positive with SOX</arm_group_label>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <arm_group_label>Her2 Negative with SOX</arm_group_label>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Her-2 positive patients with SOXT Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), PO,BID， d1-14 Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks.</description>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>S-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>HER-2 Negative Patients：SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas&lt;1.25m2) , 100mg(Body Surface Areas&gt;1.25m2, &lt;1.5 m2), 120 mg／day(Body Surface Areas&gt;1.5m2), PO,BID， d1-14 Every 3 weeks</description>
    <arm_group_label>Her2 Positive with SOX</arm_group_label>
    <arm_group_label>Her2 Positive with SOXT</arm_group_label>
    <arm_group_label>Her2 Negative with SOX</arm_group_label>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks</description>
    <arm_group_label>Her2 Negative with DOS</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>S-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Pathologically confirmed gastric cancer or gastroesophageal junction adenocarcinoma

          2. Significant HER-2 status:

             positive defined as: immunohistochemistry+ + + or FISH（fluorescence in situ
             hybridization） +. T negative define as: immunohistochemistry 0 ~ +, or
             immunohistochemistry++, and FISH negative.

          3. T3-4, any N stage of gastric cancer or gastro esophageal carcinoma (seventh edition of
             AJCC).

          4. Chemotherapy and radiotherapy naïve.

          5. Aging from 18-70.

          6. ECOG(Eastern Cooperative Oncology Group ) 0-1

          7. Available Organ function: Neutrophils&gt;2g/L， Hemoglobin &gt;9g/L， Blood platelet &gt;100g/L；
             Alanine aminotransferase（ALT） and Aspartate aminotransferase( AST) &lt;1.5 ULN(upper
             limit of normal )； Total bilirubin(TBIL)&lt;1.0 ULN; Cr &lt;1.0 ULN

          8. Left ventricular ejection fraction&gt;50%

          9. Written informed consent.

        Exclusion criteria:

          1. Other pathology Type Other than adenocarcinoma, such as squamous cell carcinoma

          2. History of allergies to drugs in the study

          3. Intraperitoneal dissemination or distant metastasis

          4. Digestive tract obstruction or uncontrollable recurrent bleeding ,clinical significant
             ascites

          5. Dysphagia

          6. Any cause of cirrhosis

          7. Cardiac function NYHA(New York Heart Association) &gt;I degrees

          8. Previous myocardial infarction, unstable angina, stroke ,or uncontrollable Arrhythmia

          9. Any surgical contraindication

         10. Any chemotherapy or radiotherapy history

         11. Any surgical resection history of gastric cancer

         12. History of any other tumors except cured cutaneum carcinoma or carcinoma in situs of
             cervix

         13. Any contraindication for chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Ai Ping, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Ai Zhou, Phd</last_name>
    <phone>13691161998</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Xue, PHD</last_name>
    <phone>13801204967</phone>
    <email>xueqi02@139.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Ai Zhou, PHD</last_name>
      <phone>13691161998</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <contact_backup>
      <last_name>liang Zhao, PHD</last_name>
      <phone>18611110507</phone>
      <email>drzhaoliang@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ping Ai Zhou, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

